Neurocrine biosciences announces commercial availability of crenessity™ (crinecerfont) for children and adults with classic congenital adrenal hyperplasia

Crenessity, a first-in-class treatment for classic congenital adrenal hyperplasia (cah), is now commercially available in the u.s. cah-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through pantherx rare, a specialty pharmacy neurocrine access support is available to provide free, comprehensive access and support information to patients, caregivers and healthcare providers san diego , dec. 20, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced crenessity™ (crinecerfont) is now commercially available in the united states. crenessity was recently approved by the u.s. food and drug administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (cah).
NBIX Ratings Summary
NBIX Quant Ranking